Gilead GS9620 Prediction

[djxpress]

I am making a prediction that this drug will be released by Gilead in 2017/2018.

Why?  Gilead loses the patent on Viread in 2017/2018.  Their cash cow will have run its course and they will be more than happy to release this drug to continue to reap the money for HBV treatment.  

There is one thing I remember Dr. Gish telling me that I won't forget.  He said "you know Gilead is working on a drug that will make it so you don't have to take Viread for ever.  It's kind of odd that they'd be working on a drug that will eliminate their Viread income".  

Not really.  If they release it when Viread loses patent, it's a win-win for them!

[djxpress]

Had appt with Gish - he said there is unreleased data from clinical trials showing GS 9620 has been effective, and non-toxic in escalating doses.  He also said clinical trials are still ongoing and they've relaxed the inclusion criteria, so others may be able to join (veteranB).

[djxpress]

Actually there are 4, if you include the sRNAi from Arrowhead Research.

[OrientS]

So,
Now, we have three horses running in the course: rep9ac(replicor), mycrludex and GS9620 ..

Good ,, i hope number of horses will increase ..
at least one of them reach to the finalist soooon ..

[stef2011]

i do hope myrcludex and replicor are able to fasten this process or imiquimod itself show some effect, this is the only thing to make them move very fast

[calmama]

Really?  They already have a small amount of data on hbvers (human), not just healthy volunteers?  Were they cured?  If so, that would be truly exciting.

[djxpress]

They've already done small cohort human trials, and the drug works and is well tolerated.  

[calmama]

"I am making a prediction that this drug will be released by Gilead in 2017/2018. "

Provided that GS9620 shows the expected efficacy on hbvers (and hcvers).